Costco Wholesale Corp. has filed a lawsuit against Johnson & Johnson, accusing the medical device and drug giant’s Vision Care, Inc., of engaging in price fixing with its contact lenses, The Wall Street Journal reports. The lawsuit was made public in Johnson & Johnson’s recent quarterly report to the U.S. Securities and Exchange Commission.
According to the report, Costco filed the complaint in March of ...
continue reading...
The U.S. Food and Drug Administration (FDA) has given Boehringer Ingelheim’s antidote to its problematic anticoagulant drug Pradaxa a fast-track review, FiercePhrama reports. According to the company, this will make Pradaxa the first “next generation” anticoagulant to receive an FDA-approved antidote.
Last year, the German drug manufacturer Boehringer Ingelheim agreed to pay $650 million to settle roughly 4,000 Pradaxa lawsuits in state and federal courts. Plaintiffs ...
continue reading...
A California man has filed a Xarelto lawsuit against multiple pharmaceutical companies for damages allegedly caused by the blood-thinning medication. The plaintiff claims that the defendants, including Johnson & Johnson’s Janssen Pharmaceuticals, overstated the efficacy and safety of Xarelto. The complaint alleges that no antidote exists for Xarelto in the event of hemorrhagic complications.
Like plaintiffs in other Xarelto lawsuits, the California man alleges that the defendants failed ...
continue reading...
The results of AstraZeneca’s recent trials for its blood-thinning drug Brilinta show a decreased risk of post–heart attack heart problems but an increased risk of major bleeding after using the drug. The pharmaceutical company’s large-scale PEGASUS-TIMI 54 trial included 21,000 patients who had suffered at least one heart attack in the past three years. Patients received either a high dose of Brilinta, a low dose of Brilinta, or a placebo drug. All patients ...
Expanded Use of Xarelto was rejected by the FDA three times. In June of 2012, the Food and Drug Administration refused to approve the drug designed as a replacement for older-generation blood thinners like warfarin in patients with acute coronary syndrome (ACS). The agency cited concerns over the manufacturers’, Johnson and Johnson and Bayer, failure to present enough information for them to accurately determine the drug’s potential impacts. ...
A Rhode Island man has filed a Xarelto lawsuit against multiple pharmaceutical companies for injuries related to the drug. The plaintiff claimed that the defendants, including Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, received a letter from the FDA in 2013 requesting that they stop improper promotion of their product. The plaintiff further claimed that there is no antidote to the blood-thinning properties of Xarelto, in the ...
